(Total Views: 470)
Posted On: 11/09/2020 3:20:22 PM
Post# of 36557
GenerexBiotechnology
@GenerexBiotech
·
11m
We are currently in ex-Vivo human studies for an Ii-Key #SARSCoV2vaccine using predictive algorithms and our proprietary Ii-Key technology platform to provide safe and long-lasting immunity from #COVID19. To learn more about this technology, visit http://Nugenerexio.com.
Came from the hub board.
(1)
(0)Scroll down for more posts ▼
